Exploring Available Treatment Approaches for Patients With HER2-Positive Breast Cancer
William J. Gradishar, MD, discusses the current standard of care for patients with HER2-positive breast cancer, as well as some other promising therapies in this space.
William J. Gradishar, MD, chief of hematology and oncology, department of medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the current standard of care for patients with HER2-positive breast cancer, as well as some other promising therapies in this space.
The current standard for frontline therapy in HER2-positive metastatic breast cancer remains a taxmen, either trastuzumab (Herceptin) or pertuzumab (Perjeta). T-DM1 is the standard for second-line therapy in this setting, and for the third-line, a number of therapies are available, such as the recently approved tucatinib (Tukysa).
T-DM1 remains where it is now, Gradishar says, but there is an effort to move the other drugs up. Clinical trials are comparing trastuzumab deruxtecan to T-DM1, while other studies are exploring tucatinib with T-DM1 versus T-DM1 alone. These are all predictable efforts to try to move a competitor drug up, either alone or in combination with T-DM1.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
